Enzymatic DNA molecules |
| The present invention thus contemplates a synthetic or engineered (i.e., non-naturally-occurring) ... |
|
Multigene vectors |
| The present invention provides a method for preparing HSV vectors. The method comprises co-... |
|
Composition and method for inhibiting platelet aggregation |
| OF THE INVENTION This invention is provides a method of preventing or treating diseases or ... |
|
Nucleic acid probes |
| OF THE INVENTION "Derivatizable" nucleotides are nucleotides modified so as to include at the 4-... |
|
Substrate for detection of mammalian 5-C-DNA methyltransferase |
| OF THE INVENTION "Oligomeric DNA" or ODN, as used herein, means a DNA having from 10 to 75 "purine ... |
|
Vinyl ethers of nucleoside analogs |
| OF THE INVENTION The compounds of the present invention can exist as optical isomers. Both the ... |
|
Nucleoside analogs |
| OF THE INVENTION The compounds of the present invention can exist as optical isomers. Both the ... |
|
Hydrophobic multicomponent heparin conjugates, a preparing method and a use thereof |
| To accomplish those objectives, the present invention provides hydrophobic muiticomponent heparin ... |
|
Gas permeable bioreactor and method of use |
| OF THE PREFERRED EMBODIMENTS Like numbered apparatus elements in FIGS. 1-11 are the same. R... |
|
|
Membrane-resident steroid receptors and methods of use thereof
| Details |
Inventors: Rothman, Joel H.; Newman-Smith, Erin; Broitman-Maduro, Gina;
Assignee: The Regents of the University of California (Oakland, CA)
Primary Examiner: Spector; Lorraine
Assistant Examiner: Shafer; Shulamith H.
Attorney, Agent or Firm: Aston; David J. Peters, Verny, Jones, Schmitt & Aston, LLP
This invention pertains to the discovery that DPR-1 encodes a putative nuclear hormone receptor (NHR) that, based on gene reporter studies, is expressed in the endoderm throughout the life of the worm. NHR family members are transcriptional regulators that are activated when bound to their small lipophilic ligands such as steroids. While some NHRs are localized to the nucleus, others are cytoplasmic in the absence of ligand and translocate to the nucleus upon ligand binding. Once in the nucleus, they bind target sequences and regulate gene expression. |
|
DETAILED DESCRIPTION This invention pertains to the discovery that DPR-1 (formerly known as END-2) a putative nuclear hormone receptor (NHR) that, based on gene reporter studies, is expressed in the endoderm throughout the life of the worm C. elegans. NHR family members are transcriptional regulators that are activated when bound to their small lipophilic ligands such as steroids. While some NHRs are localized to the nucleus, others are cytoplasmic in the absence of ligand and translocate to the nucleus upon ligand binding. Once in the nucleus, they bind target sequences and regulate gene expression. We have found that while DPR-1 is present in the nucleus during early development, unexpectedly, it appears to localize to the plasma membrane under certain conditions later in development. DPR-1 antibody reveals nuclear expression of the protein in posterior cells of early embryos (pre-bean stage), consistent with RNA in situ analysis. However, by the bean stage, DPR-1 antigen relocalizes to the plasma membranes of developing gut cells. This membrane association continues through to hatching. Our preliminary biochemical results further indicate that DPR-1 partially associates with the membrane fraction obtained from both early and late embryos based on western blot analysis of embryonic extracts. We found that in larvae, DPR-1 antigen is either primarily cytoplasmic (and nuclear-excluded) or is localized to the membrane, depending on the preparation examined. The variable localization of DPR-1 to the cytoplasm or membrane in larvae is attributable to variations in environmental conditions. When C. elegans is grown in uncrowded conditions, DPR-1 is present throughout the cytoplasm of gut cells. However, when they are cultured at high density, the protein appears to partition to the membrane. The effect of crowding on DPR-1 localization may be a response to dauer pheromone. This intriguing localization pattern of DPR-1 is atypical for NHRs and suggests a possible novel mode of action. One postulate is that membrane-associated DPR-1 transduces a signal from the membrane
|
| Related patents |
|
|
Process for integration of a chosen gene on the chromosome of a bacterium using Mu transposons
One aim of the invention is to describe a method for amplifying and stably fixing the copies of chosen genes in a microorganism with more flexibility and more ...
|
|
|
Transposon-based transformation vectors
I claim: 1. A vector for inserting an exogenous gene into a chromosome of a eukaryotic cell, comprising: (a) a gene encoding a bacterial transposase; (b) two transposon ...
|
|
|
Methods and compositions for sensitive and rapid, functional identification of genomic polynucleotides and secondary screening capabilities
OF THE INVENTION Definitions Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary ...
|
|
|
Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells
OF THE INVENTION Tc1 belongs to the Tc1/mariner superfamily of transposons found in nematodes, arthropods and chordates (Henikoff 1992; Raddice et al. 1994; Robertson 19...
|
|
|
DNA-based transposon system for the introduction of nucleic acid into DNA of a cell
OF THE PREFERRED EMBODIMENTS The present invention relates to novel tranposases and the transposon that are used to introduce nucleic acid sequences into the DNA of a ...
|
|
|
Methods for diagnosing sepsis
The present invention provides a pharmaceutical composition for treating conditions (diseases) mediated by the inflammatory cytokine cascade, comprising an effective ...
|
|
|
Low aromatics composition
The inventions claimed is: 1. A solvent composition comprising (a) a hydrocarbon component in an amount within the range of 91 99 vol. % of said composition; and (b) an ...
|
|
|
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
The present invention describes a covalently-linked complex (CLC) for targeting a defined population of cells, comprising a targeting protein; a cytotoxic agent; and an ...
|
|
|
Compositions and methods for drug delivery using pH sensitive molecules
We claim: 1. A process for transfecting a nucleic acid into a cell in vivo, comprising: a) attaching a membrane activity inhibitor to a membrane active peptide via a ...
|
|
|
Chiral peptide nucleic acid monomers and oligomers
What is claimed is: 1. A peptide nucleic acid monomer having the formula: ##STR5## wherein: B is a naturally or non-naturally ocurring nucleobase; n is 0, 1, 2, or 3; ...
|
|
|